Older observational studies in cirrhosis and heart failure (HF) suggest that treatment with spironolactone is frequently associated with hyponatraemia, which is mechanistically plausible given the known actions of aldosterone. However, the effect of the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) f...
R. Ono, K. Docherty, A. Henderson et al.· European Heart Journal· 0 citations
Background:
Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...
Henri Lu, B. Claggett, G. Filippatos et al.· Circulation· 0 citations
Background:
Patients with type 2 diabetes (T2D) remain at high risk for adverse outcomes after acute coronary syndrome (ACS). High-sensitivity C-reactive protein (hsCRP) may identify residual risk in this setting.
Objective:
To evaluate whether baseline hsCRP is associated with all-cause mortality (ACM) and he...
V. Anagnostopoulou, Guang K. Zhang, N. Girerd et al.· Circulation· 0 citations
Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...
N. Chew, Chandramouli Chanchal, W. Tay et al.· Open Heart· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.